State of New Jersey Common Pension Fund D Has $3.18 Million Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

State of New Jersey Common Pension Fund D reduced its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 13.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,064 shares of the company’s stock after selling 8,457 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Apellis Pharmaceuticals were worth $3,176,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of APLS. Jennison Associates LLC raised its stake in Apellis Pharmaceuticals by 79.8% during the 3rd quarter. Jennison Associates LLC now owns 3,542,209 shares of the company’s stock valued at $134,746,000 after purchasing an additional 1,571,606 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Apellis Pharmaceuticals by 109.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock valued at $128,400,000 after buying an additional 1,121,497 shares in the last quarter. Polar Capital Holdings Plc raised its stake in shares of Apellis Pharmaceuticals by 126.6% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company’s stock valued at $40,089,000 after buying an additional 588,875 shares in the last quarter. Fiera Capital Corp raised its stake in shares of Apellis Pharmaceuticals by 74.2% in the 3rd quarter. Fiera Capital Corp now owns 919,690 shares of the company’s stock valued at $34,985,000 after buying an additional 391,770 shares in the last quarter. Finally, Victory Capital Management Inc. raised its stake in shares of Apellis Pharmaceuticals by 84.2% in the 3rd quarter. Victory Capital Management Inc. now owns 738,511 shares of the company’s stock valued at $28,093,000 after buying an additional 337,554 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Stock Up 4.0 %

Shares of NASDAQ:APLS opened at $49.86 on Friday. Apellis Pharmaceuticals, Inc. has a 12 month low of $19.83 and a 12 month high of $94.75. The company’s 50-day moving average price is $57.84 and its two-hundred day moving average price is $57.44. The company has a quick ratio of 2.50, a current ratio of 3.10 and a debt-to-equity ratio of 0.48. The firm has a market cap of $6.01 billion, a P/E ratio of -11.13 and a beta of 0.88.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, hitting analysts’ consensus estimates of ($0.73). The firm had revenue of $146.38 million for the quarter, compared to analyst estimates of $143.34 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The company’s revenue was up 545.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.50) EPS. As a group, research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.34 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on APLS. Jefferies Financial Group upgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price objective for the company from $68.00 to $80.00 in a research note on Monday, February 5th. Robert W. Baird restated an “outperform” rating and issued a $81.00 price objective on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. Oppenheimer increased their price objective on shares of Apellis Pharmaceuticals from $75.00 to $79.00 and gave the company an “outperform” rating in a research note on Tuesday, January 30th. Needham & Company LLC restated a “buy” rating and issued a $85.00 price objective on shares of Apellis Pharmaceuticals in a research note on Thursday. Finally, HC Wainwright restated a “buy” rating and issued a $92.00 price objective on shares of Apellis Pharmaceuticals in a research note on Friday. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $77.93.

Insider Activity

In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 69,107 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $54.17, for a total value of $3,743,526.19. Following the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at $60,452,799.11. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 18,681 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $57.18, for a total value of $1,068,179.58. Following the transaction, the director now owns 173,998 shares of the company’s stock, valued at $9,949,205.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Pascal Deschatelets sold 69,107 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the completion of the transaction, the insider now directly owns 1,115,983 shares in the company, valued at approximately $60,452,799.11. The disclosure for this sale can be found here. In the last quarter, insiders have sold 381,011 shares of company stock valued at $23,463,657. 7.50% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).